GLS.NS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 13:00):

Glenmark Life Sciences Limited develops, manufactures, and supplies non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India...

Stats
Šios dienos apimtis	584 260
Vidutinė apimtis	163 641
Rinkos kapitalizacija	99.85B
EPS	INR9.69 ( 2023-10-20 )
Last Dividend	INR21.00 ( 2023-03-24 )
Next Dividend	INR0 ( N/A )
P/E	19.22
ATR14	INR1.542 (0.19%)

Tūris Koreliacija

Ilgas: 0.35 (neutral)

Trumpas: 0.40 (neutral)

Signal:(40.464) Neutral

Glenmark Life Sciences Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
APCOTEXIND.NS	0.907
AMIORG.NS	0.849
RAMKY.NS	0.83
RAMRAT.NS	0.814
MAXVIL.NS	0.811
GMRINFRA.NS	0.801

10 Labiausiai neigiamai susiję koreliacijos
LTGILTBEES.NS	-0.87

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Glenmark Life Sciences Koreliacija - Valiuta/Žaliavos

0.45
( neutral )

0.10
( neutral )

-0.81
( strong negative )

0.38
( neutral )

0.39
( neutral )

-0.52
( weak negative )

Glenmark Life Sciences Finansinės ataskaitos

Annual	2023
Pajamos:	INR22.83B
Bruto pelnas:	INR12.81B (56.11 %)
EPS:	INR38.43

FY	2023
Pajamos:	INR22.83B
Bruto pelnas:	INR12.81B (56.11 %)
EPS:	INR38.43

FY	2022
Pajamos:	INR21.61B
Bruto pelnas:	INR11.47B (53.08 %)
EPS:	INR38.11

FY	2022
Pajamos:	INR21.23B
Bruto pelnas:	INR10.80B (50.88 %)
EPS:	INR35.63

Financial Reports:

No articles found.

Glenmark Life Sciences Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR10.50 (N/A)	INR0 (N/A)	INR21.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Glenmark Life Sciences Dividend Information - Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.63 - Stable (12.69%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR10.50	2021-11-22
Last Dividend	INR21.00	2023-03-24
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	3	--
Total Paid Out	INR42.00	--
Avg. Dividend % Per Year	1.99%	--
Score	4.06	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.63
Div. Directional Score	9.12	--

Next Divdend (Est)
(2024-12-18)

INR0 Estimate 0.00 %

Dividend Stability

0.07 Very Bad

Dividend Score

4.06

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2021	INR10.50	1.40%
2022	INR10.50	1.68%
2023	INR21.00	5.03%
2024	INR0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
TIPSINDLTD.NS	Dividend Junior	2023-08-03	Annually	17	0.03%
PEL.NS	Dividend Junior	2023-06-16	Annually	29	1.59%
JAICORPLTD.NS	Dividend Junior	2023-09-04	Annually	17	0.27%
DBCORP.NS	Dividend Knight	2023-08-01	Semi-Annually	15	3.47%
SIGIND.NS	Ex Dividend Junior	2023-09-22	Annually	11	0.62%
MAZDA.NS	Dividend Junior	2023-09-07	Annually	8	1.43%
GUFICBIO.NS	Dividend Junior	2023-09-21	Annually	20	0.04%
BASF.NS	Dividend Junior	2023-07-20	Annually	23	0.18%
PRECWIRE.NS	Dividend Junior	2023-08-28	Semi-Annually	23	1.28%
KALYANIFRG.NS	Dividend Junior	2023-09-13	Annually	17	0.81%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.206	1.500	5.88	8.81	[0 - 0.5]
returnOnAssetsTTM	0.165	1.200	4.49	5.39	[0 - 0.3]
returnOnEquityTTM	0.204	1.500	8.85	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	4.37	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	2.64	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	0.687	1.500	7.29	10.00	[0.2 - 2]
debtRatioTTM	0.00602	-1.500	9.90	-10.00	[0 - 0.6]
interestCoverageTTM	408.14	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	6.61	2.00	7.80	10.00	[0 - 30]
freeCashFlowPerShareTTM	6.61	2.00	6.69	10.00	[0 - 20]
debtEquityRatioTTM	0.00735	-1.500	9.97	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.561	1.000	3.98	3.98	[0.2 - 0.8]
operatingProfitMarginTTM	0.276	1.000	6.47	6.47	[0.1 - 0.6]
cashFlowToDebtRatioTTM	4.72	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.801	0.800	7.99	6.39	[0.5 - 2]
Total Score				12.61

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	21.21	1.000	7.96	0	[1 - 100]
returnOnEquityTTM	0.204	2.50	9.26	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	6.61	2.00	7.80	10.00	[0 - 30]
dividendYielPercentageTTM	2.76	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	6.61	2.00	7.80	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	2.29	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0355	1.000	-1.613	0	[0.1 - 0.5]
Total Score				5.63

Glenmark Life Sciences

Glenmark Life Sciences Limited develops, manufactures, and supplies non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers Olmesartan, Amiodarone, Telmisartan, Perindopril, Rosuvastatin, and Cilostazol for cardiovascular diseases; Oxcarbazepine, Zonisamide, Topiramate, Bupropion, Ropinirole, Riluzole, and Lacosamide for central nervous system diseases; Glimepiride, Teneligliptin, Vildagliptin, and Linagliptin for diabetes; and Etoricoxib and Lornoxicam for pain management. It also provides Atovaquone, Voriconazole, Mirabegron, Desloratadine, Esomeprazole Magnesium, Adapalene, and Fluconazole gastro-intestinal disorders, anti-infective, respiratory, anti-emetic, and other therapeutic areas. In addition, the company offers contract development and manufacturing services to a range of multinational pharmaceutical and specialty pharmaceutical companies. It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was incorporated in 2011 and is based in Mumbai, India. Glenmark Life Sciences Limited is a subsidiary of Glenmark Pharmaceuticals Limited.